2Mayumi T,Takezawa J,Takahashi H,et al. Low-dose intramuscular polymyxin B improves survival of septic rats. Shock,1999,11:82 - 86.
3Saladino RA, Stack AM, Thompson C, et al. High-dose recombinant endotoxin neutralizing protein improves survival in rabbits, with Escherichia coil sepsis. Crit Care Med, 1996,24:1203 -1207.
4Fletcher MA, kloczewiak M, Loiselle PM, et al. TALF peptide-immunoglobulin conjugates that bind lipopolysaccharide. J Endotoxin Re-seaarch, 1996, 3:49.
5Scott MG, Vreugdenhil AC,Buurman WA, et al. Cutting edge:cationic antimicrobial peptides block the binding of lipopolysaccharide(LPS) to LPS binding protein. J lmmunol, 2000,164:549 - 553.
6Kellogg TA, Weiss CA, Johnston JW, et al. Antiendotoxin agents share molecular homology within their lipopolysaccharide binding domains. J Surg Res,1999,85:136 - 141.
7Steven AM ,James PT. Design of Gram-negative selective antimicrobial peptides. Biochemisty,2001 ,40:5777 - 5785.
8Sorensen OE ,Follin P. Human cathelicidin, hCAP-18, is processed to the antimicrolfial peptide LL-37 by extracelluar cleavage with proteinase 3. Blood ,2001,97:3951 - 3959.
9Akashi S,Shimazu R,Ogata H,et al. Cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J lmmunol, 2000, 164:3471 -3475.
10Brightbill HD,Modlin RL. Toll-like receptor: molecular mechanisms of the mammalian immune response. Immunology, 2000,101:1-10.
